Prelude Therapeutics raises $25M via pre-funded warrant private placement for SMARCA2 pipeline

Prelude Therapeutics Inc

Gross proceeds ~$25M from sale of 7,936,759 pre-funded warrants at $3.1499 each, exercise price $0.0001.
Net proceeds estimated at $24.9M after offering expenses.
Funds primarily support SMARCA2 portfolio: IV molecule PRT3789 clinical development and oral program IND.
Cash runway now expected into 2026; closing expected Dec 13, 2023.
Warrants are immediately exercisable, subject to 4.99% beneficial ownership cap (waivable to 19.99%).

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Prelude Therapeutics Inc entered into Amended and Restated Registration Rights Agreement with the Company and the Purchasers (effective 2023-12-11).

Action: entry
Counterparty: the Company and the Purchasers
Effective: 2023-12-11

Exact text from the filing

the Company and the Purchasers also entered into an Amended and Restated Registration Rights Agreement, dated as of December 11, 2023 (the “ Amended and Restated Registration Rights Agreement ”), providing for the registration for resale of the shares of Common Stock underlying the Pre-Funded Warrants

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Prelude Therapeutics Inc entered into Securities Purchase Agreement with certain institutional accredited investors (effective 2023-12-11).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional accredited investors
Effective: 2023-12-11

Exact text from the filing

On December 11, 2023, Prelude Therapeutics Incorporated, a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement pre-funded warrants (the “ Pre-Funded Warrants ”) to purchase up to 7,936,759 shares of the Company’s voting common stock, par value $0.0001 per share (the “ Common Stock ”), at a price of $3.1499 per warrant with an exercise price of $0.0001 per share

View on SEC.gov

273 material agreements filed in the last 30 days. Browse all material agreements →

Prelude Therapeutics Inc filing history →

Source: SEC EDGAR

accession 0000950170-23-069210

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.